How did the FDA change tanning-bed rules?
FDA withdraws proposed tanning-bed ban for minors
The FDA has backed away from a prior regulatory effort aimed at restricting indoor tanning for minors. A proposed rule that would have barred Americans under 18 from using tanning beds was withdrawn, ending a long-running push to tighten standards around youth exposure.
The change unfolded amid political and public pressure, with coverage indicating that the FDA’s reversal happened alongside support from Robert F. Kennedy Jr. and response from medical groups concerned about indoor tanning’s health harms. While the withdrawal means the specific proposed ban did not take effect, the FDA action signals that the agency is not moving forward with that particular regulatory approach.
Why it matters
Indoor tanning has been a persistent public health concern because ultraviolet exposure increases the risk of skin cancers, including melanoma. Restrictions for minors are typically justified on the basis that early-life UV exposure compounds long-term cancer risk. When proposed bans are withdrawn, public health advocates often worry that young people may continue to access services at an age when prevention benefits are greatest.
What remains unknown
The stories describe the withdrawal of the proposed rule, but they don’t lay out what alternative federal actions—if any—might replace the effort to restrict minors. Details about timing for any new proposal or enforcement strategy were not provided.
Bottom line
The FDA’s decision to stop pursuing the proposed minor ban means that the regulatory landscape for youth indoor tanning is not tightening via that rulemaking process. The case highlights how health policy can become entangled with broader political dynamics, potentially affecting timelines for protective public measures.